Current management of fallopian tube carcinoma

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 1, 2002, Pages 27-32

  Gadducci, Angiolo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ABDOMINAL HYSTERECTOMY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; FEMALE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; LYMPHADENECTOMY; OVARY CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; STOMATITIS; TREATMENT INDICATION; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; OVARIECTOMY; PACLITAXEL;

EID: 0036183166     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200202000-00005     Document Type: Review

References (72)

1. Fallopian tube carcinoma
2. Fallopian tube adenocarcinoma: Common extraperitoneal recurrence
3. Primary fallopian tube cancer: A review of the literature
4. Carcinoma of the fallopian tube: A clinicopathological study of 105 cases with observations on staging and prognostic factors
5. Incidence of malignant fallopian tube tumors
6. Carcinoma of the fallopian tube. Management and sites of failure
7. Primary carcinoma of the fallopian tube: Evidence for activity of cisplatin combination therapy
8. Prognostic features of carcinoma of the fallopian tube
9. c-erbB-2 and p53 expression in fallopian tube carcinoma
10. Treatment of primary fallopian tube carcinoma with cisplatin-containing chemotherapy
11. Adenocarcinoma of the fallopian tube: Results of a multi-institutional retrospective analysis of 72 patients
12. Fallopian tube cancer: The Roswell Park Experience
13. Carcinoma of the fallopian tube: Clinical management
14. Clues to the pathogenesis of fallopian tube carcinoma: A morphological and immunohistochemical case control study
15. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families
16. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: A case report
17. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations
18. A genetic epidemiological study of carcinoma of the fallopian tube
19. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis
20. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery
21. Primary carcinoma of the fallopian tube: Comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations
22. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube
23. p53 expression in fallopian tube carcinomas
24. Recurrent fallopian tube carcinoma: TP53 mutation and clinical course
25. Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma
26. Cancer of the fallopian tube
27. Adenocarcinoma of the fallopian tube
28. Long-term survival of a patient with fallopian tube cancer presenting with a supraclavicular mass
29. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: A Cooperation Task Force (CTF) study
30. Inguinal lymph node metastasis: An unusual presentation of fallopian tube carcinoma
31. Preoperative diagnosis of primary fallopian tube carcinoma
32. Preoperative diagnosis of the primary fallopian tube carcinoma by three-dimensional static and power Doppler sonography
33. Carcinoma of the fallopian tube
34. Management and prognosis of primary fallopian tube carcinoma
35. Primary carcinoma of the fallopian tube. A report of 19 cases with literature review
36. Carcinoma of the fallopian tube. Clinicopathologic study of 151 patients treated at the Norwegian Radium Hospital
37. Primary fallopian tube carcinoma: The Queensland experience
38. Carcinoma of the fallopian tube: A clinical and histopathologic review. The Radiumhemmet series
39. Primary carcinoma of the fallopian tube
40. Carcinoma of the fallopian tube. Clinical analysis of 40 cases
41. The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma. A multicenter study
42. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma
43. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
44. Fallopian tube cancer: The role of radiation therapy
45. The relevance of adjuvant therapy in primary carcinoma of the fallopian tube, stages I and II: Irradiation vs. chemotherapy
46. Primary adenocarcinoma localized to the fallopian tubes: Report on 33 cases
47. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery
48. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide
49. Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube
50. Combination chemotherapy in advanced adenocarcinoma of the fallopian tube
51. Primary fallopian tube adenocarcinoma: Clinical complete response after salvage treatment with high-dose paclitaxel
52. Metachronous carcinoma of the vulva and fallopian tube
53. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study
54. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens
55. Diagnostic dilemmas and current therapy of Fallopian tube cancer
56. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube
57. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma
58. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum
59. Second-look laparotomy in carcinoma of the fallopian tube
60. Second-line treatment of ovarian cancer
61. Second-line treatment and consolidation therapies in advanced ovarian cancer
62. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
63. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
64. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
65. Complete response to topotecan of recurrent fallopian tube carcinoma
66. A phase I trial of a 3-day topotecan q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum
67. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
68. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
69. Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer
70. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum
71. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
72. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer